Tango Shares Plunge After 3Q Loss, Product Plans

Dow Jones11-06

By Rob Curran

Shares of Tango Therapeutics plunged after it logged a wider third-quarter loss and said it would test a cancer drug in combination with another company's product candidate.

The Boston biotech firm posted a third-quarter loss of $29.2 million, or 27 cents a share, wider than the loss of $22.3 million, or 23 cents a share, in the prior-year period.

Revenue inched up to $11.6 million from $10.7 million.

During the quarter, Tango said its TNG462 cancer-drug candidate showed promise in an early-stage phase 1/2 clinical trial, prompting the company to advance the treatment through a development program. The biotech firm struck a deal with rival Revolution Medicines to test TNG462 in combination with Revolution's RAS$(ON)$ multi- and G12D-selective inhibitors.

Tango said Maeve Waldron-Lynch joins as senior vice president and head of clinical development later in November.

Shares of Tango plunged 35% to $3.38, premarket.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

November 06, 2024 09:14 ET (14:14 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481607215?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 22:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481607215","market":"hk","top_or_hot":-1,"title":"Tango Shares Plunge After 3Q Loss, Product Plans","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Tango <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> plunged after it logged a wider third-quarter loss and said it would test a cancer drug in combination with another company's product candidate. \n</p>\n<p>\n  The Boston biotech firm posted a third-quarter loss of $29.2 million, or 27 cents a share, wider than the loss of $22.3 million, or 23 cents a share, in the prior-year period. \n</p>\n<p>\n  Revenue inched up to $11.6 million from $10.7 million. \n</p>\n<p>\n  During the quarter, Tango said its TNG462 cancer-drug candidate showed promise in an early-stage phase 1/2 clinical trial, prompting the company to advance the treatment through a development program. The biotech firm struck a deal with rival Revolution Medicines to test TNG462 in combination with Revolution's RAS<a href=\"https://laohu8.com/S/ON\">$(ON)$</a> multi- and G12D-selective inhibitors. \n</p>\n<p>\n  Tango said Maeve Waldron-Lynch joins as senior vice president and head of clinical development later in November. \n</p>\n<p>\n  Shares of Tango plunged 35% to $3.38, premarket. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 06, 2024 09:14 ET (14:14 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tango Shares Plunge After 3Q Loss, Product Plans</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTango Shares Plunge After 3Q Loss, Product Plans\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-06 22:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Rob Curran \n\n\n \n\n\n  Shares of Tango Therapeutics plunged after it logged a wider third-quarter loss and said it would test a cancer drug in combination with another company's product candidate. \n\n\n...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2357305700.SGD","symbol_name":"Allianz Global Artificial Intelligence ET H2-SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2481607215","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481607215","pubTimestamp":1730902440,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Tango Therapeutics plunged after it logged a wider third-quarter loss and said it would test a cancer drug in combination with another company's product candidate.The Boston biotech firm posted a third-quarter loss of $29.2 million, or 27 cents a share, wider than the loss of $22.3 million, or 23 cents a share, in the prior-year period.Revenue inched up to $11.6 million from $10.7 million.During the quarter, Tango said its TNG462 cancer-drug candidate showed promise in an early-stage phase 1/2 clinical trial, prompting the company to advance the treatment through a development program. The biotech firm struck a deal with rival Revolution Medicines to test TNG462 in combination with Revolution's RAS multi- and G12D-selective inhibitors.Tango said Maeve Waldron-Lynch joins as senior vice president and head of clinical development later in November.Shares of Tango plunged 35% to $3.38, premarket.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU2298322129.HKD":"BGF SUSTAINABLE ENERGY \"A2\" (HKDHDG) ACC","LU0724618433.USD":"BGF NEW ENERGY \"A4\" (USD) INC","IE00BZ199S13.USD":"BNY MELLON MOBILITY INNOVATION \"B\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","TNGX":"Tango Therapeutics Inc.","LU0124384867.USD":"贝莱德新能源基金A2","LU1861214812.USD":"Blackrock Future of Transport A2 USD","BK4588":"碎股","LU1861219969.SGD":"Blackrock Future of Transport A2 SGD-H","BK4141":"半导体产品","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","IE00BD6J9T35.USD":"NEUBERGER BERMAN NEXT GENERATION MOBILITY \"A\" (USD) ACC","LU1861215975.USD":"贝莱德新一代科技基金 A2","LU1548497426.USD":"安联环球人工智能AT Acc","LU1861220033.SGD":"Blackrock Next Generation Technology A2 SGD-H","LU2360107325.USD":"BGF FUTURE OF TRANSPORT \"A4\" (USD) INC","ON":"安森美半导体","BK4512":"苹果概念","LU1978683503.SGD":"Blackrock Sustainable Energy A2 SGD-H","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC"},"translate_title":"Tango股价在第三季度亏损和产品计划后暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ON":1,"TNGX":0.9},"content_text":"By Rob Curran \n\n\n \n\n\n  Shares of Tango Therapeutics plunged after it logged a wider third-quarter loss and said it would test a cancer drug in combination with another company's product candidate. \n\n\n  The Boston biotech firm posted a third-quarter loss of $29.2 million, or 27 cents a share, wider than the loss of $22.3 million, or 23 cents a share, in the prior-year period. \n\n\n  Revenue inched up to $11.6 million from $10.7 million. \n\n\n  During the quarter, Tango said its TNG462 cancer-drug candidate showed promise in an early-stage phase 1/2 clinical trial, prompting the company to advance the treatment through a development program. The biotech firm struck a deal with rival Revolution Medicines to test TNG462 in combination with Revolution's RAS$(ON)$ multi- and G12D-selective inhibitors. \n\n\n  Tango said Maeve Waldron-Lynch joins as senior vice president and head of clinical development later in November. \n\n\n  Shares of Tango plunged 35% to $3.38, premarket. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 06, 2024 09:14 ET (14:14 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481607215"}